Stock Track | Novo Nordisk Surges 5.05% on Stellar Q4 Results, Strong Wegovy Sales and Supply Updates

Stock Track

Feb 05, 2025

Novo Nordisk's (NVO) stock soared 5.05% in pre-market trading on Wednesday, following the Danish pharmaceutical giant's impressive fourth-quarter earnings and sales performance, driven by the continued success of its blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic.

The company reported better-than-expected Q4 earnings of $0.88 per share, surpassing analysts' estimates of $0.83. Sales for the quarter jumped 30% year-over-year to $11.97 billion, exceeding expectations of $11.24 billion. Wegovy sales more than doubled to $2.77 billion, while Ozempic sales rose 12% to $4.74 billion, both beating forecasts.

Novo Nordisk's robust financial results were fueled by the soaring demand for its innovative GLP-1 drugs, which have been widely embraced by healthcare providers and patients alike. However, the company acknowledged that it expects periodic supply constraints and related drug shortage notifications across several products and geographies in 2025, as it grapples with the challenges of meeting the surging demand.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1198859439"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1198859439\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1198859439?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-05 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198859439","market":"hk","top_or_hot":-1,"title":"Stock Track | Novo Nordisk Surges 5.05% on Stellar Q4 Results, Strong Wegovy Sales and Supply Updates","media":"Stock Track","content":"<p>Novo Nordisk's (NVO) stock soared 5.05% in pre-market trading on Wednesday, following the Danish pharmaceutical giant's impressive fourth-quarter earnings and sales performance, driven by the continued success of its blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic.</p>\n\n<p>The company reported better-than-expected Q4 earnings of $0.88 per share, surpassing analysts' estimates of $0.83. Sales for the quarter jumped 30% year-over-year to $11.97 billion, exceeding expectations of $11.24 billion. Wegovy sales more than doubled to $2.77 billion, while Ozempic sales rose 12% to $4.74 billion, both beating forecasts.</p>\n\n<p>Novo Nordisk's robust financial results were fueled by the soaring demand for its innovative GLP-1 drugs, which have been widely embraced by healthcare providers and patients alike. However, the company acknowledged that it expects periodic supply constraints and related drug shortage notifications across several products and geographies in 2025, as it grapples with the challenges of meeting the surging demand.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo Nordisk Surges 5.05% on Stellar Q4 Results, Strong Wegovy Sales and Supply Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo Nordisk Surges 5.05% on Stellar Q4 Results, Strong Wegovy Sales and Supply Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-05 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novo Nordisk's (NVO) stock soared 5.05% in pre-market trading on Wednesday, following the Danish pharmaceutical giant's impressive fourth-quarter earnings and sales performance, driven by the continued success of its blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic.</p>\n\n<p>The company reported better-than-expected Q4 earnings of $0.88 per share, surpassing analysts' estimates of $0.83. Sales for the quarter jumped 30% year-over-year to $11.97 billion, exceeding expectations of $11.24 billion. Wegovy sales more than doubled to $2.77 billion, while Ozempic sales rose 12% to $4.74 billion, both beating forecasts.</p>\n\n<p>Novo Nordisk's robust financial results were fueled by the soaring demand for its innovative GLP-1 drugs, which have been widely embraced by healthcare providers and patients alike. However, the company acknowledged that it expects periodic supply constraints and related drug shortage notifications across several products and geographies in 2025, as it grapples with the challenges of meeting the surging demand.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1198859439","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198859439","pubTimestamp":1738766412,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novo Nordisk's  stock soared 5.05% in pre-market trading on Wednesday, following the Danish pharmaceutical giant's impressive fourth-quarter earnings and sales performance, driven by the continued success of its blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic.The company reported better-than-expected Q4 earnings of $0.88 per share, surpassing analysts' estimates of $0.83. Sales for the quarter jumped 30% year-over-year to $11.97 billion, exceeding expectations of $11.24 billio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"诺和诺德(Novo Nordisk)第四季度业绩出色、Wegovy销售和供应强劲，股价飙升5.05%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk's (NVO) stock soared 5.05% in pre-market trading on Wednesday, following the Danish pharmaceutical giant's impressive fourth-quarter earnings and sales performance, driven by the continued success of its blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic.\nThe company reported better-than-expected Q4 earnings of $0.88 per share, surpassing analysts' estimates of $0.83. Sales for the quarter jumped 30% year-over-year to $11.97 billion, exceeding expectations of $11.24 billion. Wegovy sales more than doubled to $2.77 billion, while Ozempic sales rose 12% to $4.74 billion, both beating forecasts.\nNovo Nordisk's robust financial results were fueled by the soaring demand for its innovative GLP-1 drugs, which have been widely embraced by healthcare providers and patients alike. However, the company acknowledged that it expects periodic supply constraints and related drug shortage notifications across several products and geographies in 2025, as it grapples with the challenges of meeting the surging demand.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}